alcohol-related%20liver%20disease
ALCOHOL-RELATED LIVER DISEASE

Alcoholic liver disease diagnosis is suggested by an established history of habitual alcohol intake of sufficient length and intensity.
Signs of alcohol abuse and hepatic injury include malnutrition and muscle wasting, cutaneous telangiectasia, palmar erythema, finger clubbing, Dupuytren's contracture, peripheral neuropathy, parotid gland enlargement and signs of gynecomastia and hypogonadism may also be present. Patient may also be asymptomatic.

 

Alcohol-related%20liver%20disease Signs and Symptoms

Introduction

Patient may present with signs and symptoms related to portal hypertension:
  • Abdominal wall collaterals
  • Ascites
  • Splenomegaly
  • Venous hum
  • Hepatic encephalopathy

Signs and Symptoms

Signs of Alcohol Abuse and Hepatic Injury

  • Malnutrition and muscle wasting
  • Jaundice
  • Cutaneous telangiectasia
  • Palmar erythema
  • Finger clubbing
  • Dupuytren’s contracture
  • Rhinophyma
  • Spider angioma
  • Peripheral neuropathy
  • Parotid gland enlargement
  • Signs of gynecomastia and hypogonadism may also be present

Others

  • Patient may be asymptomatic
  • Hepatomegaly, which is the most common sign in patients with alcohol-related liver disease (ALD)
  • Hepatic bruit
  • Alcohol withdrawal (eg tremors, tachycardia, agitation, delirium tremens)
  • Anorexia, weight loss
  • Systemic inflammatory response syndrome (SIRS) (≥2 of the following: Heart rate >100 beats/minute, respiratory rate >12 breaths/minute, temperature >38°C or <36°C, WBC count >12,000 or <4000 mm)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 2 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.